Get the Weekly Intelligence Brief — top committee picks every Sunday.
WAY · NASDAQ · STOCK

Waystar Holding (WAY) Stock Analysis

Healthcare Updated October 10, 2026
$26.66
52W $17.26 – $40.35
59/100
$5.12B
37.1
0.07
AI Committee Verdict
Watch
59/100
Conviction: Moderate · 60% agreement · 5 analysts
+1.3%
-13.8%
0.09:1
Moderate

Is WAY Bullish or Bearish?

Mixed. Innellis AI committee rates Waystar Holding Corp. (WAY) Watch with a composite score of 59/100 , based on 5 analysts with 60% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +1.25 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -18.75 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Supporting evidence favours the bullish case. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • EPS growing 46.4% YoY — Growth
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • P/E of 37.5 is moderate-to-rich — Value
  • ROE of only 3.6% -- cheap may mean cheap for a reason — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • No news coverage in the last 14 days -- limited independent confirmation either way — News
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
59/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 40%
of 192 Healthcare peers
Value Analyst neutral
49 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 37.5 is moderate-to-rich
Growth Analyst bullish
62 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 46.4% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
60 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
− No news coverage in the last 14 days -- limited independent confirmation either way
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 58.8 to 58.8.

Analyst-level changes:
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
62.8
Neutral
MACD Histogram
0.091
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$22.97
Resistance
$27.00
Bollinger %B
0.83
Inside Bands
Price vs Moving Averages
EMA 9
$26.00 Above
EMA 21
$25.60 Above
EMA 50
$24.82 Above
EMA 200
$25.63 Above

Fundamental Analysis

Valuation
71
Growth
50
Profitability
47
Financial Health
94
Cash Flow
70
Valuation
P/E Ratio 37.1×
P/B Ratio 1.28×
PEG Ratio 0.84
Dividend Yield 0.00%
52W High $40.35
52W Low $17.26
Quality & Growth
ROE 289.0%
ROA 193.8%
Gross Margin 6910.6%
Operating Margin 2287.0%
Revenue Growth YoY —
Debt / Equity 0.37
AI Fundamental Assessment
P/E ratio of 37.1 (rich relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of 0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 2.9%; Return on assets of 1.9%; Net margin of 11.2%; Gross margin of 69.1%; Current ratio of 1.85 (healthy short-term liquidity); Debt-to-equity of 0.37; Free cash flow per share is positive (1.28); Most recent quarter beat estimates by 7.4%; 2 consecutive earnings beats; EPS growth decelerating (+16.7% -> +2.4% QoQ); Analyst estimates flat over recent quarters
Get the Full WAY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime